Ikena Historical Financial Ratios

IKNA Stock

USD 1.35 0.04 2.88%

Ikena Oncology is lately reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.66 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Ikena Oncology financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

About Ikena Financial Ratios Analysis

Ikena OncologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ikena Oncology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ikena financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ikena Oncology history.

Ikena Oncology Financial Ratios Chart

At present, Ikena Oncology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 2.74, whereas Price To Sales Ratio is forecasted to decline to 9.81.

Price To Sales Ratio Average Payables Payables Turnover Capex To Revenue

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Ikena Oncology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ikena Oncology sales, a figure that is much harder to manipulate than other Ikena Oncology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most ratios from Ikena Oncology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 2.74, whereas Price To Sales Ratio is forecasted to decline to 9.81.

	2022	2023	2024	2025 (projected)
Interest Debt Per Share	0.22	0.26	0.16	0.15
Revenue Per Share	0.43	0.22	0.2	0.29

Interest Debt Per Share Revenue Per Share

Ikena Oncology fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow
Price To Sales Ratio		-0.92	-0.69	0.69	0.48	0.36	-0.43	-0.92	1.0	0.48	-1.0	0.08	0.47	0.99	-0.88	-0.98	-0.43	-0.71	-0.98	-0.65	-0.17	0.94	-0.99	-0.4	-0.99	-0.99
Ptb Ratio	-0.92		0.88	-0.82	-0.73	-0.43	0.36	1.0	-0.92	-0.73	0.9	-0.29	-0.69	-0.89	0.88	0.87	0.5	0.51	0.87	0.77	0.49	-0.98	0.87	0.7	0.89	0.87
Book Value Per Share	-0.69	0.88		-0.78	-0.76	-0.29	0.27	0.88	-0.69	-0.76	0.66	-0.36	-0.68	-0.64	0.74	0.65	0.34	0.27	0.65	0.67	0.57	-0.86	0.65	0.73	0.64	0.65
Free Cash Flow Yield	0.69	-0.82	-0.78		0.73	0.37	0.11	-0.82	0.69	0.72	-0.63	0.61	0.93	0.64	-0.55	-0.65	-0.44	-0.52	-0.65	-0.93	-0.46	0.86	-0.65	-0.78	-0.61	-0.65
Operating Cash Flow Per Share	0.48	-0.73	-0.76	0.73		0.13	-0.32	-0.73	0.48	1.0	-0.44	0.77	0.69	0.38	-0.67	-0.34	-0.15	0.11	-0.34	-0.55	-0.89	0.63	-0.35	-0.91	-0.43	-0.35
Average Payables	0.36	-0.43	-0.29	0.37	0.13		0.26	-0.43	0.37	0.12	-0.33	-0.14	0.51	0.36	-0.1	-0.35	-0.95	-0.43	-0.35	-0.57	-0.17	0.45	-0.35	-0.4	-0.33	-0.34
Capex To Depreciation	-0.43	0.36	0.27	0.11	-0.32	0.26		0.36	-0.43	-0.34	0.49	0.01	0.32	-0.4	0.73	0.37	-0.31	-0.19	0.37	-0.31	0.21	-0.25	0.39	-0.02	0.49	0.39
Pb Ratio	-0.92	1.0	0.88	-0.82	-0.73	-0.43	0.36		-0.92	-0.73	0.9	-0.29	-0.69	-0.89	0.88	0.87	0.5	0.51	0.87	0.77	0.49	-0.98	0.87	0.7	0.89	0.87
Ev To Sales	1.0	-0.92	-0.69	0.69	0.48	0.37	-0.43	-0.92		0.48	-1.0	0.08	0.47	0.99	-0.88	-0.98	-0.43	-0.71	-0.98	-0.65	-0.17	0.94	-0.98	-0.4	-0.99	-0.98
Free Cash Flow Per Share	0.48	-0.73	-0.76	0.72	1.0	0.12	-0.34	-0.73	0.48		-0.45	0.77	0.68	0.39	-0.67	-0.34	-0.14	0.11	-0.34	-0.54	-0.89	0.63	-0.36	-0.9	-0.43	-0.35
Roic	-1.0	0.9	0.66	-0.63	-0.44	-0.33	0.49	0.9	-1.0	-0.45		-0.03	-0.39	-0.99	0.9	0.98	0.38	0.69	0.98	0.59	0.14	-0.91	0.98	0.34	1.0	0.98
Net Income Per Share	0.08	-0.29	-0.36	0.61	0.77	-0.14	0.01	-0.29	0.08	0.77	-0.03		0.61	-0.02	-0.21	0.02	0.15	0.24	0.03	-0.37	-0.64	0.26	0.02	-0.69	-0.01	0.02
Payables Turnover	0.47	-0.69	-0.68	0.93	0.69	0.51	0.32	-0.69	0.47	0.68	-0.39	0.61		0.41	-0.3	-0.42	-0.6	-0.37	-0.42	-0.93	-0.55	0.72	-0.42	-0.87	-0.38	-0.42
Capex To Revenue	0.99	-0.89	-0.64	0.64	0.38	0.36	-0.4	-0.89	0.99	0.39	-0.99	-0.02	0.41		-0.85	-0.99	-0.42	-0.76	-0.99	-0.63	-0.08	0.91	-0.99	-0.31	-0.99	-0.99
Cash Per Share	-0.88	0.88	0.74	-0.55	-0.67	-0.1	0.73	0.88	-0.88	-0.67	0.9	-0.21	-0.3	-0.85		0.82	0.13	0.33	0.81	0.41	0.41	-0.81	0.83	0.45	0.9	0.83
Pocfratio	-0.98	0.87	0.65	-0.65	-0.34	-0.35	0.37	0.87	-0.98	-0.34	0.98	0.02	-0.42	-0.99	0.82		0.41	0.79	1.0	0.63	0.0	-0.91	1.0	0.27	0.98	1.0
Interest Coverage	-0.43	0.5	0.34	-0.44	-0.15	-0.95	-0.31	0.5	-0.43	-0.14	0.38	0.15	-0.6	-0.42	0.13	0.41		0.5	0.41	0.68	0.21	-0.52	0.4	0.47	0.38	0.4
Capex To Operating Cash Flow	-0.71	0.51	0.27	-0.52	0.11	-0.43	-0.19	0.51	-0.71	0.11	0.69	0.24	-0.37	-0.76	0.33	0.79	0.5		0.8	0.65	-0.39	-0.65	0.78	-0.01	0.7	0.78
Pfcf Ratio	-0.98	0.87	0.65	-0.65	-0.34	-0.35	0.37	0.87	-0.98	-0.34	0.98	0.03	-0.42	-0.99	0.81	1.0	0.41	0.8		0.63	0.0	-0.91	1.0	0.27	0.98	1.0
Days Payables Outstanding	-0.65	0.77	0.67	-0.93	-0.55	-0.57	-0.31	0.77	-0.65	-0.54	0.59	-0.37	-0.93	-0.63	0.41	0.63	0.68	0.65	0.63		0.38	-0.82	0.62	0.74	0.58	0.62
Income Quality	-0.17	0.49	0.57	-0.46	-0.89	-0.17	0.21	0.49	-0.17	-0.89	0.14	-0.64	-0.55	-0.08	0.41	0.0	0.21	-0.39	0.0	0.38		-0.34	0.02	0.89	0.12	0.02
Roe	0.94	-0.98	-0.86	0.86	0.63	0.45	-0.25	-0.98	0.94	0.63	-0.91	0.26	0.72	0.91	-0.81	-0.91	-0.52	-0.65	-0.91	-0.82	-0.34		-0.92	-0.62	-0.9	-0.91
Ev To Operating Cash Flow	-0.99	0.87	0.65	-0.65	-0.35	-0.35	0.39	0.87	-0.98	-0.36	0.98	0.02	-0.42	-0.99	0.83	1.0	0.4	0.78	1.0	0.62	0.02	-0.92		0.28	0.98	1.0
Pe Ratio	-0.4	0.7	0.73	-0.78	-0.91	-0.4	-0.02	0.7	-0.4	-0.9	0.34	-0.69	-0.87	-0.31	0.45	0.27	0.47	-0.01	0.27	0.74	0.89	-0.62	0.28		0.32	0.28
Return On Tangible Assets	-0.99	0.89	0.64	-0.61	-0.43	-0.33	0.49	0.89	-0.99	-0.43	1.0	-0.01	-0.38	-0.99	0.9	0.98	0.38	0.7	0.98	0.58	0.12	-0.9	0.98	0.32		0.98
Ev To Free Cash Flow	-0.99	0.87	0.65	-0.65	-0.35	-0.34	0.39	0.87	-0.98	-0.35	0.98	0.02	-0.42	-0.99	0.83	1.0	0.4	0.78	1.0	0.62	0.02	-0.91	1.0	0.28	0.98

Click cells to compare fundamentals

Ikena Oncology Account Relationship Matchups

Ikena Oncology fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	124.78	14.56	6.16	8.98	10.32	9.81
Ptb Ratio	(11.35)	2.17	0.65	0.48	0.63	0.66
Book Value Per Share	(2.82)	5.78	4.06	4.07	2.61	2.74
Free Cash Flow Yield	(0.0336)	(0.14)	(0.78)	(0.97)	(0.58)	(0.61)
Operating Cash Flow Per Share	(1.06)	(1.67)	(2.05)	(1.91)	(0.95)	(1.0)
Stock Based Compensation To Revenue	0.2	0.17	0.48	0.83	0.75	0.79
Capex To Depreciation	2.55	3.24	1.91	0.41	0.37	0.35
Pb Ratio	(11.35)	2.17	0.65	0.48	0.63	0.66
Ev To Sales	107.13	7.29	2.69	(2.94)	(3.38)	(3.21)
Free Cash Flow Per Share	(1.08)	(1.72)	(2.09)	(1.92)	(0.95)	(1.0)
Roic	(0.3)	(0.36)	(0.15)	(0.44)	(0.41)	(0.46)
Net Income Per Share	(1.23)	(0.95)	(1.84)	(1.63)	(1.02)	(1.07)
Payables Turnover	21.13	19.76	0.97	0.49	0.57	0.54
Sales General And Administrative To Revenue	0.96	0.58	1.42	2.72	2.45	2.57
Research And Ddevelopement To Revenue	4.88	1.52	4.12	6.51	7.49	10.59
Capex To Revenue	0.0833	0.0568	0.0916	0.0452	0.052	0.0494
Cash Per Share	4.53	6.45	4.34	4.2	2.58	2.85
Pocfratio	(30.33)	(7.49)	(1.3)	(1.03)	(1.72)	(1.81)
Capex To Operating Cash Flow	(0.0203)	(0.0292)	(0.0193)	(0.005192)	(0.004673)	(0.004906)
Pfcf Ratio	(29.73)	(7.27)	(1.27)	(1.03)	(1.72)	(1.81)
Days Payables Outstanding	17.27	18.47	375.59	739.3	665.37	698.64
Income Quality	0.85	1.77	1.08	1.17	0.93	0.98
Roe	0.44	(0.16)	(0.45)	(0.4)	(0.39)	(0.37)
Ev To Operating Cash Flow	(26.04)	(3.75)	(0.57)	0.34	(1.03)	(1.08)
Pe Ratio	(25.92)	(13.22)	(1.44)	(1.21)	(1.61)	(1.69)
Return On Tangible Assets	(0.2)	(0.26)	(0.14)	(0.39)	(0.35)	(0.37)
Ev To Free Cash Flow	(25.52)	(3.64)	(0.56)	0.34	(1.03)	(1.08)
Earnings Yield	(0.0386)	(0.0756)	(0.69)	(0.83)	(0.62)	(0.65)
Net Debt To E B I T D A	3.67	6.7	0.77	1.47	0.54	0.51
Current Ratio	5.86	8.7	7.44	12.58	11.8	6.3
Tangible Book Value Per Share	(2.82)	5.78	4.06	4.07	2.61	2.74
Shareholders Equity Per Share	(2.82)	5.78	4.06	4.07	2.61	2.74
Debt To Equity	(0.001841)	0.0336	0.0387	0.0633	0.0597	0.0627
Capex Per Share	0.0214	0.0489	0.0395	0.00992	0.008928	0.008481
Graham Net Net	(2.98)	5.34	3.64	3.67	2.25	2.37
Revenue Per Share	0.26	0.86	0.43	0.22	0.2	0.29
Interest Debt Per Share	0.005188	0.19	0.22	0.26	0.16	0.15
Debt To Assets	0.001104	0.0282	0.0331	0.0559	0.0531	0.0505
Enterprise Value Over E B I T D A	(22.27)	(6.72)	(0.6)	0.36	(0.8)	(0.84)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:

How To Invest In Ikena

Details

Is Ikena Stock a good investment?

Details

What is Ikena Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.02)

Revenue Per Share

0.014

Quarterly Revenue Growth

(0.88)

Return On Assets

(0.20)

Return On Equity

(0.33)

The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Ikena Historical Financial Ratios

About Ikena Financial Ratios Analysis

Ikena Oncology Financial Ratios Chart

Price To Sales Ratio

Average Payables

Payables Turnover

Capex To Revenue

Ikena Oncology fundamentals Correlations

Ikena Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ikena Oncology fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Return On Tangible Assets	+ 1.0	Roic
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Roic	- 1.0	Ev To Sales
Roic	- 1.0	Price To Sales Ratio
Ev To Free Cash Flow	- 0.99	Capex To Revenue
Return On Tangible Assets	- 0.99	Capex To Revenue
Ev To Operating Cash Flow	- 0.99	Capex To Revenue
Pfcf Ratio	- 0.99	Capex To Revenue